Cannabis-Tobacco Co-Use Treatment Study
Randomized Controlled Trial of Varenicline to Treat Tobacco and Cannabis Co-Use (RECLAIM)
Medical University of South Carolina
200 participants
May 6, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of the RECLAIM study is to evaluate the effectiveness of varenicline (sometimes known as Chantix) compared to placebo (an inactive substance) for the treatment of cigarettes and cannabis (marijuana). Varenicline is not FDA approved for the combination treatment of cigarette abstinence and cannabis reduction or abstinence. All participants will also receive counseling and access to online treatment modules during a quit attempt for cigarettes and a reduction attempt for cannabis. This study is being conducted by the Medical University of South Carolina. All procedures are conducted remotely and there is no in-person visits are needed. To qualify, participants must be 18 or older, live in South Carolina, use cigarettes and cannabis, and are interested in quitting cigarettes and reducing cannabis.
Eligibility
Inclusion Criteria8
- Ages 18 and over (no upper age limit)
- Must smoke at least 5 tobacco cigarettes per day on at least 20 out of the past 30 days for the past 3 months
- Must express interest in quitting tobacco
- Must express interest in cannabis reduction and/or cessation
- Must submit a positive instant-read test for cotinine and cannabis prior to enrollment
- Must self-report cannabis use (THC-dominant products) on at 3 days per week out of the past 30 days
- Must be willing to take varenicline or placebo for 12 weeks
- Must reside in South Carolina
Exclusion Criteria4
- Any significant or acutely unstable medical, psychiatric, or substance use problem (including clinically significant disorders) that would contraindicate research, interfere with safety, compromise data integrity, or preclude consistent study participation
- Pregnant or trying to become pregnant
- Use of medications with smoking cessation efficacy
- Regular use of e-cigarettes or other tobacco products (\<10 days in the past month)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be randomized 1:1 to varenicline or matched placebo. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1 mg b.i.d. starting on Day 8. Dosing of 2 mg per day will be maintained for the next 11 weeks.
Research staff will provide skills-based counseling at weekly visits. Weekly counseling sessions will include discussion of online intervention modules, while providing skills-based strategies focused on enlisting social support, recognizing triggers, managing craving/withdrawal/stress, etc. Staff will use motivational enhancement techniques to address tobacco cessation, cannabis reduction or abstinence, and medication adherence.
Participants will have access to online modules addressing tobacco and cannabis co-use to support cessation and/or reduction. Content includes 12 virtual modules combining cognitive behavioral therapy (CBT) and motivational enhancement (MET) to address tobacco, cannabis, and their co-use.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06883162